Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.
Article
CAS
PubMed
Google Scholar
Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11:219–38.
Article
CAS
PubMed
Google Scholar
The Antibody Society. In: Approved antibodies. Jun 27, 2019 https://www.antibodysociety.org/ Accessed 15 Jul 2019.
Lefranc MP. IMGT, the International ImMunoGeneTics Information System. Cold Spring Harb Protoc. 2011;2011:595–603.
PubMed
Google Scholar
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14.
Article
CAS
PubMed
Google Scholar
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984;81:6851–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Foster RH, Wiseman LR. Abciximab. An updated review of its use in ischaemic heart disease. Drugs. 1998;56:629–65.
Article
CAS
PubMed
Google Scholar
Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188–95.
Article
CAS
PubMed
Google Scholar
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266–74.
Article
CAS
PubMed
Google Scholar
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321:522–5.
Article
CAS
PubMed
Google Scholar
Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods. 2005;36:69–83.
Article
CAS
PubMed
Google Scholar
Watier H, Reichert J. Evolution of antibody therapeutics. In: Vaughan T, Osbourn J, Jallal B, editors. Protein terapeutics. Weinheim: Wiley-VCH Verlag GmbH & Co, KGaA; 2017. p. 25–49.
Chapter
Google Scholar
McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348:552–4.
Article
CAS
PubMed
Google Scholar
Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315–7.
Article
CAS
PubMed
Google Scholar
Wu CH, Liu IJ, Lu RM, Wu HC. Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci. 2016;23:8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis. 1999;58(Suppl 1):I70–2.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371:1639–40.
Article
PubMed
Google Scholar
Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11:81–9.
CAS
PubMed
Google Scholar
Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–96.
Article
CAS
PubMed
Google Scholar
Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood. 2008;111:1094–100.
Article
CAS
PubMed
Google Scholar
Reddy GK, Nadler E, Jain VK. Denosumab (AMG 162), a Fully Human Monoclonal Antibody Against RANK Ligand Activity. Support Cancer Ther. 2005;3:14–5.
Article
CAS
PubMed
Google Scholar
Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005;7:588–97.
CAS
PubMed
Google Scholar
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Roth EM, Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Futur Cardiol. 2014;10:183–99.
Article
CAS
Google Scholar
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–8.
Article
PubMed
CAS
Google Scholar
Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. Circ J. 2014;78:1073–82.
Article
CAS
PubMed
Google Scholar
Chioato A, Noseda E, Stevens M, Gaitatzis N, Kleinschmidt A, Picaud H. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin Vacc Immunol: CVI. 2012;19:1597–602.
Article
CAS
Google Scholar
Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, et al. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73:595–604.
Article
CAS
PubMed
Google Scholar
Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.
Article
CAS
PubMed
Google Scholar
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66.
Article
CAS
PubMed
Google Scholar
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299–308.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–34.
Article
CAS
PubMed
Google Scholar
Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34.
Article
CAS
PubMed
Google Scholar
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379:341–51.
Article
CAS
PubMed
Google Scholar
Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. 1994;368:856–9.
Article
CAS
PubMed
Google Scholar
Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997;15:146–56.
Article
CAS
PubMed
Google Scholar
Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet. 1994;7:13–21.
Article
CAS
PubMed
Google Scholar
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279–86.
Article
CAS
PubMed
Google Scholar
Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6:29–31.
Article
PubMed
Google Scholar
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.
Article
CAS
PubMed
Google Scholar
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127:2209–21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31.
Article
PubMed
PubMed Central
CAS
Google Scholar
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377:809–18.
Article
CAS
PubMed
Google Scholar
Kyowa Hakko Kirin Co. Ltd. Consolidated Financial Summary (IFRS) Fiscal 2018. 2019, February 5.
Grilo AL, Mantalaris A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019;37:9–16.
Article
CAS
PubMed
Google Scholar
Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Next generation immune-checkpoints for cancer therapy. J Thorac Dis. 2018;10:S1581–S601.
Article
PubMed
PubMed Central
Google Scholar
Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis. 2018;9:147–58.
Article
CAS
PubMed
PubMed Central
Google Scholar
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72:517–24.
Article
CAS
PubMed
Google Scholar
Zamora-Atenza C, Diaz-Torne C, Geli C, Diaz-Lopez C, Ortiz MA, Moya P, et al. Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid arthritis. Arthritis Res Ther. 2014;16:R153.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–56.
Article
CAS
PubMed
Google Scholar
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–9.
Article
CAS
PubMed
Google Scholar
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015;21:4286–93.
Article
CAS
PubMed
Google Scholar
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016;374:2542–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy. 2019;11:889–901.
Article
CAS
PubMed
Google Scholar
Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823–33.
Article
CAS
PubMed
Google Scholar
Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Clin Cancer Res. 2016;22:3713–7.
Article
CAS
PubMed
Google Scholar
US Food and Drug Administration. FDA approves novel preventive treatment for migraine. 2018, May 17.
Paemeleire K, MaassenVanDenBrink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Curr Opin Neurol. 2018;31:274–80.
Article
CAS
PubMed
Google Scholar
Liang YL, Khoshouei M, Deganutti G, Glukhova A, Koole C, Peat TS, et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature. 2018;561:492–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–50.
Article
CAS
PubMed
Google Scholar
Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med. 2009;361:135–44.
Article
CAS
PubMed
Google Scholar
Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis. 1998;178:1555–61.
Article
CAS
PubMed
Google Scholar
Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379:645–54.
Article
CAS
PubMed
Google Scholar
Sanofi EL. FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma. Paris, 2019.
Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, et al. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018;14:1035–47.
Article
CAS
PubMed
Google Scholar
Novartis AG. Novartis Financial Results – Q2 2018. July 18, 2018 https://www.novartis.com/news/novartis-financial-results-q2-2018 Accessed 15 Jul 2019.
TESARO Inc. TESARO Announces Data Presentations at ESMO 2018 Congress. Oct 20, 2018 https://www.globenewswire.com/news-release/2018/10/20/1624331/0/en/TESARO-Announces-Data-Presentations-at-ESMO-2018-Congress.html Accessed 15 Jul 2019.
TG Therapeutics I. TG Therapeutics announces update regarding UNITY-CLL Phase 3 trial. Sep 25, 3018 http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-update-regarding-unity-cll-phase-3 Accessed 15 Jul 2019.
Gorman SD, Clark MR. Humanisation of monoclonal antibodies for therapy. Semin Immunol. 1990;2:457–66.
CAS
PubMed
Google Scholar
Mountain A, Adair JR. Engineering antibodies for therapy. Biotechnol Genet Eng Rev. 1992;10:1–142.
Article
CAS
PubMed
Google Scholar
Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989;86:10029–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C. Antibody humanization by structure-based computational protein design. MAbs. 2015;7:1045–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Olimpieri PP, Marcatili P, Tramontano A. Tabhu: tools for antibody humanization. Bioinformatics. 2015;31:434–5.
Article
CAS
PubMed
Google Scholar
Swindells MB, Porter CT, Couch M, Hurst J, Abhinandan K, Nielsen JH, et al. abYsis: integrated antibody sequence and structure—management, analysis, and prediction. J Mol Biol. 2017;429:356–64.
Article
CAS
PubMed
Google Scholar
Abhinandan KR, Martin ACR. Analyzing the “Degree of Humanness” of Antibody Sequences. J Mol Biol. 2007;369:852–62.
Article
CAS
PubMed
Google Scholar
Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline Humanization of a Non-human Primate Antibody that Neutralizes the Anthrax Toxin, by in Vitro and in Silico Engineering. J Mol Biol. 2008;384:1400–7.
Article
CAS
PubMed
Google Scholar
Thullier P, Huish O, Pelat T, Martin ACR. The Humanness of Macaque Antibody Sequences. J Mol Biol. 2010;396:1439–50.
Article
CAS
PubMed
Google Scholar
Gao SH, Huang K, Tu H, Adler AS. Monoclonal antibody humanness score and its applications. BMC Biotechnol. 2013;13:55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs. 2012;4:445–57.
Article
PubMed
PubMed Central
Google Scholar
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–65.
Article
PubMed
PubMed Central
Google Scholar
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325.
Article
CAS
PubMed
Google Scholar
Waldmann H. Human Monoclonal Antibodies: The Benefits of Humanization. Methods Mol Biol. 1904;2019:1–10.
Google Scholar
Rebello PRUB, Hale G, Friend PJ, Cobbold SP, Waldmann H. Anti-globulin responses to rat and humanized campath-1 monoclonal antibody used to treat transplant rejection1. Transplantation. 1999;68:1417–9.
Article
CAS
PubMed
Google Scholar
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.
Article
CAS
PubMed
Google Scholar
Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26:320–5.
Article
CAS
PubMed
Google Scholar
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2010;2:256–65.
Article
PubMed
PubMed Central
Google Scholar
Bender NK, Heilig CE, Dröll B, Wohlgemuth J, Armbruster F-P, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269–74.
Article
CAS
PubMed
Google Scholar
West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122–6.
Article
CAS
PubMed
Google Scholar
Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:964–75.
Article
CAS
PubMed
Google Scholar
Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 1988;73:305–18.
Article
CAS
PubMed
Google Scholar
Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature. 1991;352:624–8.
Article
CAS
PubMed
Google Scholar
Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996;14:309–14.
Article
CAS
PubMed
Google Scholar
Breitling F, Dubel S, Seehaus T, Klewinghaus I, Little M. A surface expression vector for antibody screening. Gene. 1991;104:147–53.
Article
CAS
PubMed
Google Scholar
Barbas CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. 1991;88:7978–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display: from candidate identification to clinical practice. MAbs. 2014;6:73–85.
Article
PubMed
Google Scholar
Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindqvist E, Schier R, et al. Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A. 1998;95:6157–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32:3265–74.
Article
CAS
PubMed
Google Scholar
Bradbury ARM, Sidhu S, Dübel S, McCafferty J. Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol. 2011;29:245–54.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lerner RA. Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol. 2016;16:498–508.
Article
CAS
PubMed
Google Scholar
Weber M, Bujak E, Putelli A, Villa A, Matasci M, Gualandi L, et al. A highly functional synthetic phage display library containing over 40 billion human antibody clones. PLoS One. 2014;9:e100000.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lee TY, Wu HC, Tsao TC and Lin W; Fountain Biopharma Inc., assignee. Antibodies to interleukin-6 US patent US 9,234,035. 2016 January 12.
Wu HC, Lu RM, Chiu CY, Liu IJ and Chang YL; Academia Sinica, assignee. Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity. US patent US10,196,447. 2018 February 5.
de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999;274:18218–30.
Article
PubMed
Google Scholar
Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296:57–86.
Article
CAS
PubMed
Google Scholar
Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, Jager U, et al. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol. 2008;376:1182–200.
Article
CAS
PubMed
Google Scholar
Chan CE, Lim AP, MacAry PA, Hanson BJ. The role of phage display in therapeutic antibody discovery. Int Immunol. 2014;26:649–57.
Article
CAS
PubMed
Google Scholar
Chan CE, Chan AH, Lim AP, Hanson BJ. Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays. J Immunol Methods. 2011;373:79–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wrublewski DT. Analysis for Science Librarians of the 2018 Nobel Prize in Chemistry: Directed Evolution of Enzymes and Phage Display of Peptides and Antibodies. Sci Technol Libr. 2019:1–19.
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124.
Article
CAS
PubMed
Google Scholar
Swaminathan SK, Niu L, Waldron N, Kalscheuer S, Zellmer DM, Olin MR, et al. Identification and characterization of a novel scFv recognizing human and mouse CD133. Drug Deliv Transl Res. 2013;3:143–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nilvebrant J, Kuku G, Bjorkelund H, Nestor M. Selection and in vitro characterization of human CD44v6-binding antibody fragments. Biotechnol Appl Biochem. 2012;59:367–80.
Article
CAS
PubMed
Google Scholar
Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 2009;114:4494–502.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther. 2010;9:2131–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Larsen SA, Meldgaard T, Fridriksdottir AJ, Lykkemark S, Poulsen PC, Overgaard LF, et al. Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sections. Immunol Res. 2015;62:263–72.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun Y, Shukla GS, Weaver D, Pero SC, Krag DN. Phage-display selection on tumor histological specimens with laser capture microdissection. J Immunol Methods. 2009;347:46–53.
Article
CAS
PubMed
PubMed Central
Google Scholar
Larsen SA, Meldgaard T, Lykkemark S, Mandrup OA, Kristensen P. Selection of cell-type specific antibodies on tissue-sections using phage display. J Cell Mol Med. 2015.
Su Y, Bidlingmaier S, Lee N-K, Liu B. Combine phage antibody display library selection on patient tissue specimens with laser capture microdissection to identify novel human antibodies targeting clinically relevant tumor antigens. In: Hust M, Lim TS, editors. Phage Display: Methods and Protocols. New York: Springer New York; 2018. p. 331–47.
Chapter
Google Scholar
Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–70.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9:1410.
Article
PubMed
PubMed Central
CAS
Google Scholar
Caracciolo G. Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona. Nanoscale. 2018;10:4167–72.
Article
CAS
PubMed
Google Scholar
Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999;255:386–93.
Article
CAS
PubMed
Google Scholar
Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007;6:2737–46.
Article
CAS
PubMed
Google Scholar
Maruyama T, Parren PW, Sanchez A, Rensink I, Rodriguez LL, Khan AS, et al. Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis. 1999;179(Suppl 1):S235–9.
Article
CAS
PubMed
Google Scholar
Flego M, Di Bonito P, Ascione A, Zamboni S, Carattoli A, Grasso F, et al. Generation of human antibody fragments recognizing distinct epitopes of the nucleocapsid (N) SARS-CoV protein using a phage display approach. BMC Infect Dis. 2005;5:73.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kang X, Yang BA, Hu Y, Zhao H, Xiong W, Yang Y, et al. Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display. Clin Vacc Immunol: CVI. 2006;13:953–7.
Article
CAS
Google Scholar
Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007;25:1421–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lerner RA. Manufacturing Immunity to Disease in a Test Tube: The Magic Bullet Realized. Angew Chem Int Ed. 2006;45:8106–25.
Article
CAS
Google Scholar
Zhang X, Qi X, Zhang Q, Zeng X, Shi Z, Jin Q, et al. Human 4F5 single-chain Fv antibody recognizing a conserved HA1 epitope has broad neutralizing potency against H5N1 influenza A viruses of different clades. Antivir Res 2013;99:91–9.
Article
CAS
PubMed
Google Scholar
Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A. 2008;105:5986–91.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen Z, Wang J, Bao L, Guo L, Zhang W, Xue Y, et al. Human monoclonal antibodies targeting the haemagglutinin glycoprotein can neutralize H7N9 influenza virus. Nat Commun. 2015;6.
Wang J, Chen Z, Bao L, Zhang W, Xue Y, Pang X, et al. Characterization of Two Human Monoclonal Antibodies Neutralizing Influenza A H7N9 Viruses. J Virol. 2015.
Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio. 2014;5.
Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A. 2014;111:E2018–E26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lim CC, Woo PCY, Lim TS. Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies. Sci Rep. 2019;9:6088.
Article
PubMed
PubMed Central
CAS
Google Scholar
Walker LM, Burton DR. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol. 2018;18:297–308.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. Crit Rev Biotechnol. 2018;38:394–408.
Article
CAS
PubMed
Google Scholar
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35–45.
Article
CAS
PubMed
Google Scholar
Lindsley CW. Predictions and Statistics for the Best-Selling Drugs Globally and in the United States in 2018 and a Look Forward to 2024 Projections. ACS Chem Neurosci. 2019;10:1115.
Article
CAS
PubMed
Google Scholar
Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. 2003;334:103–18.
Article
CAS
PubMed
Google Scholar
Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10:335.
Article
CAS
PubMed
Google Scholar
Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009;525:1–27 xiii.
Article
CAS
PubMed
Google Scholar
Diaz-Serrano A, Sanchez-Torre A, Paz-Ares L. Necitumumab for the treatment of advanced non-small-cell lung cancer. Future Oncol. 2019;15:705–16.
Article
CAS
PubMed
Google Scholar
Arrieta O, Zatarain-Barron ZL, Cardona AF, Carmona A, Lopez-Mejia M. Ramucirumab in the treatment of non-small cell lung cancer. Expert Opin Drug Saf. 2017;16:637–44.
Article
PubMed
CAS
Google Scholar
Aprile G, Ferrari L, Cremolini C, Bergamo F, Fontanella C, Battaglin F, et al. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Rev Clin Pharmacol. 2016;9:877–85.
Article
CAS
PubMed
Google Scholar
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 2002;97:393–9.
Article
CAS
PubMed
Google Scholar
Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003;278:43496–507.
Article
CAS
PubMed
Google Scholar
Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. MAbs. 2016;8:1177–94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015.
Rodriguez-Vida A, Bellmunt J. Avelumab for the treatment of urothelial cancer. Expert Rev Anticancer Ther. 2018;18:421–9.
Article
CAS
PubMed
Google Scholar
Benson J, Cunningham M, Duchala C, Giles-Komar JM, Luo J, Rycyzyn MA, et al.; Janssen Biotech Inc., assignee. Anti-IL-23 antibodies, compositions, methods and uses. US patent US7807414B2. 2009.
Benson J, Carton J, Cunningham M, Orlovsky YI, Rauchenberger R and Sweet R; Janssen Biotech Inc., assignee. Anti-IL-23 antibody compositions. US patent US9714287B2. 2016.
Machado A, Torres T. Guselkumab for the Treatment of Psoriasis. Biodrugs. 2018;32:119–28.
Article
CAS
PubMed
Google Scholar
Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267–74.
Article
PubMed
Google Scholar
Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532–41.
Article
CAS
PubMed
PubMed Central
Google Scholar
Busse PJ, Farkas H, Banerji A, Lumry WR, Longhurst HJ, Sexton DJ, et al. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. BioDrugs. 2019;33:33–43.
Article
CAS
PubMed
Google Scholar
Xu C, Sui J, Tao H, Zhu Q, Marasco WA. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-region sulfation, and define CXCR4 antigenic heterogeneity. J Immunol. 2007;179:2408–18.
Article
CAS
PubMed
Google Scholar
Sheehan J and Marasco WA. Phage and Yeast Display. Microbiol Spectr. 2015;3:Aid-0028-2014.
Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004;290:29–49.
Article
CAS
PubMed
Google Scholar
Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014;9:664–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bruggemann M, Osborn MJ, Ma B, Hayre J, Avis S, Lundstrom B, et al. Human antibody production in transgenic animals. Arch Immunol Ther Exp (Warsz). 2015;63:101–8.
Article
CAS
Google Scholar
Osborn MJ, Ma B, Avis S, Binnie A, Dilley J, Yang X, et al. High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igkappa/Iglambda loci bearing the rat CH region. J Immunol. 2013;190:1481–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lee EC, Liang Q, Ali H, Bayliss L, Beasley A, Bloomfield-Gerdes T, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014;32:356–63.
Article
CAS
PubMed
Google Scholar
Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A. 2014;111:5153–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Alt FW, Keith Blackwell T, Yancopoulos GD. Immunoglobulin genes in transgenic mice. Trends Genet. 1985;1:231–6.
Article
CAS
Google Scholar
Bruggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA, et al. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci U S A. 1989;86:6709–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Taylor LD, Carmack CE, Schramm SR, Mashayekh R, Higgins KM, Kuo CC, et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. 1992;20:6287–95.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen J, Trounstine M, Alt FW, Young F, Kurahara C, Loring JF, et al. Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol. 1993;5:647–56.
Article
CAS
PubMed
Google Scholar
Chen J, Trounstine M, Kurahara C, Young F, Kuo CC, Xu Y, et al. B cell development in mice that lack one or both immunoglobulin kappa light chain genes. EMBO J. 1993;12:821–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Davies NP, Rosewell IR, Richardson JC, Cook GP, Neuberger MS, Brownstein BH, et al. Creation of mice expressing human antibody light chains by introduction of a yeast artificial chromosome containing the core region of the human immunoglobulin kappa locus. Biotechnology (N Y). 1993;11:911–4.
CAS
Google Scholar
Choi TK, Hollenbach PW, Pearson BE, Ueda RM, Weddell GN, Kurahara CG, et al. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. Nat Genet. 1993;4:117–23.
Article
CAS
PubMed
Google Scholar
Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007;25:1134–43.
Article
CAS
PubMed
Google Scholar
Hoffman W, Lakkis FG, Chalasani G. B Cells, Antibodies, and More. Clin J Am Soc Nephrol. 2016;11:137–54.
Article
CAS
PubMed
Google Scholar
Diaz M, Casali P. Somatic immunoglobulin hypermutation. Curr Opin Immunol. 2002;14:235–40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol. 2007;96:179–204.
Article
CAS
PubMed
Google Scholar
Tyagi P. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5:21–3.
Article
PubMed
Google Scholar
Den Broeder, Alfons, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29(11):2288–98.
Tyagi, Preeta, Chu E, Jain VK. Recent results and ongoing trials with panitumumab (ABXEGF), a fully human anti–epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2005;5(1):21–23.
Article
PubMed
Google Scholar
Ding, Changhai. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther. 2008;8(11):1805–14.
Article
CAS
PubMed
Google Scholar
Krupitskaya, Yelena, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs. 2009;10(6):597–605.
Kuenen, Bart, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010;16(6):1915–23.
McDermott, David F, et al. Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34(8):833–42.
Article
CAS
PubMed
Google Scholar
Boyerinas, Benjamin, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti–PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immun Res. 2015;3(10):1148–57.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sofen, Howard, et al. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–40.
Al-Salama, Zaina T. Emapalumab: first global approval. Drugs. 2019;79(1):99–103.
Article
CAS
PubMed
Google Scholar
Kreitman, Robert J, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018;32(8):1768.
Berardi R, Onofri A, Pistelli M, Maccaroni E, Scartozzi M, Pierantoni C, et al. Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid. 2010;5:61–76.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong IT, Shojania K, Dutz J, Tsao NW. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2016;16:153–66.
Article
PubMed
Google Scholar
Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, et al. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. J Immunother Cancer. 2019;7:80.
Article
PubMed
PubMed Central
Google Scholar
Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol. 2015;11:1307–26.
Article
CAS
PubMed
Google Scholar
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, et al. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018;154:1660–71.
Article
CAS
PubMed
Google Scholar
Scott CT. Mice with a human touch. Nat Biotechnol. 2007;25:1075–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol. 1994;98:323–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Aman P, Ehlin-Henriksson B, Klein G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med. 1984;159:208–20.
Article
CAS
PubMed
Google Scholar
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10:871–5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85:9998–10009.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kuppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J. 1993;12:4955–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4:372–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Obiakor H, Sehgal D, Dasso JF, Bonner RF, Malekafzali A, Mage RG. A comparison of hydraulic and laser capture microdissection methods for collection of single B cells, PCR, and sequencing of antibody VDJ. Anal Biochem. 2002;306:55–62.
Article
CAS
PubMed
Google Scholar
Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. 2008;329:112–24.
Article
CAS
PubMed
Google Scholar
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.
Article
CAS
PubMed
Google Scholar
Lagerkvist AC, Furebring C, Borrebaeck CA. Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning. Biotechniques. 1995;18:862–9.
CAS
PubMed
Google Scholar
Battye FL, Light A, Tarlinton DM. Single cell sorting and cloning. J Immunol Methods. 2000;243:25–32.
Article
CAS
PubMed
Google Scholar
Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009;343:65–7.
Article
CAS
PubMed
Google Scholar
Herzenberg LA, Parks D, Sahaf B, Perez O, Roederer M, Herzenberg LA. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem. 2002;48:1819–27.
CAS
PubMed
Google Scholar
Lundkvist A, Horling J, Athlin L, Rosen A, Niklasson B. Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nephropathia epidemica: a novel method using antigen-coated magnetic beads for specific B cell isolation. J Gen Virol. 1993;74(Pt 7):1303–10.
Article
CAS
PubMed
Google Scholar
Correa I, Ilieva KM, Crescioli S, Lombardi S, Figini M, Cheung A, et al. Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. Front Immunol. 2018;9:493.
Article
PubMed
PubMed Central
CAS
Google Scholar
Weitkamp JH, Kallewaard N, Kusuhara K, Feigelstock D, Feng N, Greenberg HB, et al. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J Immunol Methods. 2003;275:223–37.
Article
CAS
PubMed
Google Scholar
Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329:856–61.
Article
CAS
PubMed
PubMed Central
Google Scholar
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636–40.
Article
CAS
PubMed
Google Scholar
Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol. 2014;88:12233–41.
Article
PubMed
PubMed Central
CAS
Google Scholar
Woda M, Friberg H, Currier JR, Srikiatkhachorn A, Macareo LR, Green S, et al. Dynamics of Dengue Virus (DENV)-Specific B Cells in the Response to DENV Serotype 1 Infections, Using Flow Cytometry With Labeled Virions. J Infect Dis. 2016;214:1001–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Coronella JA, Telleman P, Truong TD, Ylera F, Junghans RP. Amplification of IgG VH and VL (Fab) from single human plasma cells and B cells. Nucleic Acids Res. 2000;28:E85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453:667–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jin A, Ozawa T, Tajiri K, Obata T, Kondo S, Kinoshita K, et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat Med. 2009;15:1088–92.
Article
CAS
PubMed
Google Scholar
Love JC, Ronan JL, Grotenbreg GM, van der Veen AG, Ploegh HL. A microengraving method for rapid selection of single cells producing antigen-specific antibodies. Nat Biotechnol. 2006;24:703–7.
Article
CAS
PubMed
Google Scholar
Ogunniyi AO, Story CM, Papa E, Guillen E, Love JC. Screening individual hybridomas by microengraving to discover monoclonal antibodies. Nat Protoc. 2009;4:767–82.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tajiri K, Kishi H, Tokimitsu Y, Kondo S, Ozawa T, Kinoshita K, et al. Cell-microarray analysis of antigen-specific B-cells: single cell analysis of antigen receptor expression and specificity. Cytometry A. 2007;71:961–7.
Article
PubMed
CAS
Google Scholar
Tokimitsu Y, Kishi H, Kondo S, Honda R, Tajiri K, Motoki K, et al. Single lymphocyte analysis with a microwell array chip. Cytometry A. 2007;71:1003–10.
Article
PubMed
CAS
Google Scholar
Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, et al. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine. 2012;30:4276–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chi X, Li J, Liu W, Wang X, Yin K, Liu J, et al. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine. Clin Vacc Immunol: CVI. 2015;22:553–60.
Article
CAS
Google Scholar
Rudkin FM, Raziunaite I, Workman H, Essono S, Belmonte R, MacCallum DM, et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat Commun. 2018;9:5288.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cox KS, Tang A, Chen Z, Horton MS, Yan H, Wang XM, et al. Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. MAbs. 2016;8:129–40.
Article
CAS
PubMed
Google Scholar
Iizuka A, Komiyama M, Tai S, Oshita C, Kurusu A, Kume A, et al. Identification of cytomegalovirus (CMV)pp65 antigen-specific human monoclonal antibodies using single B cell-based antibody gene cloning from melanoma patients. Immunol Lett. 2011;135:64–73.
Article
CAS
PubMed
Google Scholar
Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE Jr. Immunodominance of the VH1–46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. J Immunol. 2008;180:3279–88.
Article
CAS
PubMed
Google Scholar
Di Niro R, Mesin L, Raki M, Zheng NY, Lund-Johansen F, Lundin KE, et al. Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. J Immunol. 2010;185:5377–83.
Article
PubMed
CAS
Google Scholar
Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, et al. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nat Commun. 2018;9:4560.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bushey RT, Moody MA, Nicely NL, Haynes BF, Alam SM, Keir ST, et al. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Rep. 2016;15:1505–13.
Article
CAS
PubMed
PubMed Central
Google Scholar
Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351:1339–42.
Article
CAS
PubMed
Google Scholar
Rijal P, Elias SC, Machado SR, Xiao J, Schimanski L, O'Dowd V, et al. Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans. Cell Rep. 2019;27:172–86 e7.
Article
CAS
PubMed
Google Scholar
Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016;351:1078–83.
Article
CAS
PubMed
PubMed Central
Google Scholar
Awi NJ, Teow SY. Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now? J Pathog. 2018;2018:8724549.
Article
PubMed
PubMed Central
CAS
Google Scholar
Nogales A, Piepenbrink MS, Wang J, Ortega S, Basu M, Fucile CF, et al. A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody. Sci Rep. 2018;8:4374.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fu Y, Zhang Z, Sheehan J, Avnir Y, Ridenour C, Sachnik T, et al. A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. Nat Commun. 2016;7:12780.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nakamura G, Chai N, Park S, Chiang N, Lin Z, Chiu H, et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe. 2013;14:93–103.
Article
CAS
PubMed
Google Scholar
Chai N, Swem LR, Park S, Nakamura G, Chiang N, Estevez A, et al. A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. Nat Commun. 2017;8:14234.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gilman MS, Castellanos CA, Chen M, Ngwuta JO, Goodwin E, Moin SM, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016;1.
Article
PubMed
PubMed Central
Google Scholar
Goodwin E, Gilman MSA, Wrapp D, Chen M, Ngwuta JO, Moin SM, et al. Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation. Immunity. 2018;48:339–49 e5.
Article
CAS
PubMed
PubMed Central
Google Scholar
Doria-Rose NA, Joyce MG. Strategies to guide the antibody affinity maturation process. Curr Opin Virol. 2015;11:137–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eisen HN. Affinity enhancement of antibodies: how low-affinity antibodies produced early in immune responses are followed by high-affinity antibodies later and in memory B-cell responses. Cancer Immunol Res. 2014;2:381–92.
Article
CAS
PubMed
Google Scholar
Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341:1192–8.
Article
CAS
PubMed
Google Scholar
Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M, et al. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem. 2008;283:1156–66.
Article
CAS
PubMed
Google Scholar
Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005;23:1105–16.
Article
CAS
PubMed
Google Scholar
Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem. 2005;280:607–17.
Article
CAS
PubMed
Google Scholar
Thie H, Voedisch B, Dübel S, Hust M, Schirrmann T. Affinity Maturation by Phage Display. In: Dimitrov AS, editor. Therapeutic Antibodies. Totowa: Humana Press; 2009. p. 309–22.
Chapter
Google Scholar
Steinwand M, Droste P, Frenzel A, Hust M, Dübel S, Schirrmann T. The influence of antibody fragment format on phage display based affinity maturation of IgG. MAbs. 2013;6:204–18.
Article
PubMed Central
Google Scholar
Low NM, Holliger PH, Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol. 1996;260:359–68.
Article
CAS
PubMed
Google Scholar
Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004;248:327–43.
CAS
PubMed
Google Scholar
Nielsen UB, Marks JD. Affinity maturation of phage antibodies. In: Clackson T, Lowman HB, editors. Phage Display: A Practical Approach. Oxford: Oxford University Press; 2004. p. 360.
Google Scholar
Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019;10:1296.
Article
PubMed
PubMed Central
Google Scholar
Kelley RF, Meng YG. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. Methods Mol Biol. 2012;901:277–93.
Article
CAS
PubMed
Google Scholar
Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, et al. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J Biol Chem. 2014;289:3571–90.
Article
CAS
PubMed
Google Scholar
Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs. 2014;6:422–36.
Article
PubMed
PubMed Central
Google Scholar
Mimura Y, Katoh T, Saldova R, O'Flaherty R, Izumi T, Mimura-Kimura Y, et al. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell. 2018;9:47–62.
Article
CAS
PubMed
Google Scholar
Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017;114:3485–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen CL, Hsu JC, Lin CW, Wang CH, Tsai MH, Wu CY, et al. Crystal Structure of a Homogeneous IgG-Fc Glycoform with the N-Glycan Designed to Maximize the Antibody Dependent Cellular Cytotoxicity. ACS Chem Biol. 2017;12:1335–45.
Article
PubMed
CAS
Google Scholar
Lin CW, Tsai MH, Li ST, Tsai TI, Chu KC, Liu YC, et al. A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc Natl Acad Sci U S A. 2015;112:10611–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Neri D. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. Cancer Immunol Res. 2019;7:348–54.
Article
PubMed
PubMed Central
Google Scholar
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16:315.
Article
CAS
PubMed
Google Scholar
Larson SM, Carrasquillo JA, Cheung N-KV, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347.
Article
CAS
PubMed
PubMed Central
Google Scholar
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019.
Ohradanova-Repic A, Nogueira E, Hartl I, Gomes AC, Preto A, Steinhuber E, et al. Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells. Nanomedicine. 2018;14:123–30.
Article
CAS
PubMed
Google Scholar
Lu R-M, Chang Y-L, Chen M-S, Wu H-C. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32:3265–74.
Article
CAS
PubMed
Google Scholar
June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379:64–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.
Article
CAS
PubMed
Google Scholar
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380:45–56.
Article
CAS
PubMed
Google Scholar
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378:449–59.
Article
CAS
PubMed
PubMed Central
Google Scholar
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439–48.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017;15:31.
Article
PubMed
CAS
Google Scholar
Chen IC, Chiu YK, Yu CM, Lee CC, Tung CP, Tsou YL, et al. High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Sci Rep. 2017;7:14455.
Article
PubMed
PubMed Central
CAS
Google Scholar
Barreto K, Maruthachalam BV, Hill W, Hogan D, Sutherland AR, Kusalik A, et al. Next-generation sequencing-guided identification and reconstruction of antibody CDR combinations from phage selection outputs. Nucleic Acids Res. 2019.
Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2017;18:35.
Article
PubMed
CAS
Google Scholar
Georgiou G, Ippolito GC, Beausang J, Busse CE, Wardemann H, Quake SR. The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol. 2014;32:158.
Article
CAS
PubMed
PubMed Central
Google Scholar
Research and Markets. Global and China Monoclonal Antibody Industry Report, 2019–2025. Global, China 2019, April. 180 p.